marijuana stocks news

Cara Therapeutics to Webcast Presentation at the 15th Annual Needham Healthcare Conference

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AgraFlora Organics (AGRA) (AGFAF) Awarded Health Canada Research License at GMP-Certified Toronto, Ontario Bottling Facility and Increases Convertible Debenture Offering

VANCOUVER, British Columbia, Dec. 10, 2019 (GLOBE NEWSWIRE) — AgraFlora Organics International…

CLS Holdings USA, Inc. (CLSH) Announces Its Branded Product Division

CLS Holdings USA, Inc. Announces Its Branded Product Division, City Trees Has…

Cara Therapeutics, Inc. (CARA) Doses First Patient in Phase 1 Trial of Oral KORSUVA™

Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™…

mCig, Inc. (MCIG) Updates Shareholders on NYAcres Hemp Project and New CBD Product Line

mCig Inc. Updates Shareholders on NYAcres Hemp Project and New CBD Product…